Contribution of Cerebral 18F-DOPA PET-CT Scan in High-grade Recurrent Gliomas

Launched by CENTRAL HOSPITAL, NANCY, FRANCE · Feb 22, 2021

Keywords

ClinConnect Summary

This clinical trial is looking at the use of a special brain scan called 18F-DOPA PET-CT to help doctors more accurately identify areas of high-grade gliomas (a type of aggressive brain tumor) that need treatment. The goal is to see if this scan can provide better information about the tumor's location compared to traditional MRI scans, especially when the cancer comes back after initial treatment. This could help doctors plan more effective re-radiation treatments for patients.

To be eligible for the trial, participants must be adults aged 18 to 75 with a confirmed diagnosis of either grade III or IV glioma that has returned after treatment. They should be able to provide consent and meet certain health criteria. If you join the study, you'll undergo both the 18F-DOPA PET-CT scan and standard imaging to compare the results. This research is important because it could lead to improved treatment planning for patients dealing with recurrent brain tumors.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adult \> 18 and \< 75 years old
• • Status WHO ≤ 2
• • Histological diagnosis of WHO grade III or IV glioma, in local recurrence after radiochemotherapy (60Gy/30 sessions + concomitant TEMOZOLOMIDE), postoperatively or exclusively.
• • Recurrence in the field of initial radiotherapy
• • Indication for stereotactic radiotherapy alone, validated in neuro-oncology CPR.
• • Patient affiliated to a social security system
• • Patient able to give consent
• Exclusion Criteria:
• • Contraindication to new radiotherapy
• • First treatment other than standard radiochemotherapy (60Gy/30 session + concomitant TEMOZOLOMIDE), postoperative or exclusive.
• • Contraindication to MRI and/or gadolinium injection
• • Pregnancy, breastfeeding
• • Follow-up of the patient impossible
• • Persons deprived of liberty or under guardianship